Hartington Pharmaceutical

The interest in finding new formulas for biotechnological research, as well as discovering new products to solve some of the most significant therapeutic vacuums moved a select group of experts to come together in the 90s. In informal meetings they discussed and reviewed some of the most important medical controversies concerning the approach to treating certain ENT illnesses.

The main point of discussion among these experts was the lack of medicines capable of tackling a growing problem. Everyone coincided in expressing their concern regarding the therapeutic vacuum that existed in treating ENT diseases that were especially prevalent, such as acute and chronic rhinosinusitis, insisting above all on one unquestionable fact: “In spite of the treatment received, some 15% of acute rhinosinusitis cases actually worsened” and even after 4 weeks of treatment remain unsolved, according to recent epidemiological studies: PROSINUS 2008.

1996- Hartington Business S.L. is founded in Spain.

1997- Work is started on a compound to cure rhinosinusitis.

1998- Iveriapharma is founded in Georgia, enabling the clinical trials for Sinuforte® to commence.

2001- Development begins on a new treatment for Pharyngitis.

2002- Construction of new production plant in Georgia is completed, equipped with the latest production lines and the most advanced manufacturing resources. Investigation in to the treatment of herpes is initiated.

2004- Hartington Pharmaceutical, S.L. is founded in Spain. Sinuforte® is registered in countries in Eastern Europe and Asia.

2006- Hartington enters the Western European pharmaceutical market with the Spanish Licence for Fluirespira Forte ® from Zambon Group.

2007- Enters the pharmaceutical market of the following countries: Germany, Poland, Italy, Slovenia and Greece. Hartington Pharma Ltd is set up for the manufacture of Nasodren®.